The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). - sprookjes - yvandenbroek - TriplyDB

The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

http://www.wikidata.org/entity/Q36015358

about

P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review Marine natural products as breast cancer resistance protein inhibitors Multiple Drug Transport Pathways through Human P-Glycoprotein.Cancer stem cell metabolism: a potential target for cancer therapy Genetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoni Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1)Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.A high throughput flow cytometric assay platform targeting transporter inhibition Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos.Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.The Inhibitor Ko143 Is Not Specific for ABCG2 The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together Beyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles.A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein.Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration.CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier.A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects.Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113.Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2 PET radiotracers for imaging P-glycoprotein: the challenge for early diagnosis in AD.Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors.Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier.(11)C- and (18)F-Labeled Radioligands for P-Glycoprotein Imaging by Positron Emission Tomography.Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11 C]verapamil in elderly vs. young subjects.ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.

P2860

Q27024260-6BF3158F-340F-48E6-8CB3-2324F974DDC0 Q27027706-DBC3D161-59B9-4785-A2E9-AB0EFC54AB4F Q27301793-53502A6F-5BB5-4B87-85E0-B274DDF66179 Q28079045-8FC9203B-EE03-41D4-AFDA-4019112800BB Q28478288-6AD69E6E-A956-4E36-B7C6-BDDD507B4D7E Q28536673-74FE37B9-6A8B-4671-95BE-4AC59828183D Q28543846-B938D7B6-6693-402F-8998-21071BE58FC6 Q30274798-38D8D517-F624-4479-B4BB-FB5E67B0126F Q33912745-2FE05B58-471D-4F87-A467-DD245CC2DEF6 Q34173709-6BDC0DF2-79C1-4C76-AE1A-2072E3CFA769 Q34572780-9301E2C4-7E62-4C36-86F5-7E3CF0087F0A Q34581006-76882E36-7B47-4DA1-B02C-9CB966712189 Q35181940-296FD56A-D17B-4AC3-BFC3-9704C782BFD2 Q35267340-CA4125F7-25B6-48A0-B149-41C901B04377 Q35831488-D33E1F1A-92E8-41D7-80AC-097AA4C87E69 Q35962045-1627C8B6-DFDE-4089-A404-D201DC3BAF0C Q36137412-17CFD027-370E-4D63-AB7F-CB68DA02F26E Q36247616-2ECF8051-39B7-4B4B-9140-5CBEC018DEBB Q36386154-C556B8CC-0642-4B4F-A3F9-5D63FBABE775 Q36559641-1ACFB012-9405-41C7-A062-C22C705AB298 Q36571957-D6A3F5BE-35AD-47E3-B935-72A131AE1896 Q36618001-A0CC1D0B-053E-4BA4-8D26-0D5816CED6CA Q36638627-4D588AFE-D5A3-4C25-9158-94BFB6AE84B2 Q36910890-CC7D3DB0-4318-44BD-ABA8-9A3B85B5FFFF Q36935382-AFF1E82E-0DA5-47C6-8CD1-A54858974811 Q36947641-DC8CAB45-82E3-4B9A-BC7E-B3E58C226497 Q36949082-AC32D9C5-BE01-4305-A822-5F5BE3BDA924 Q36949407-5D4AD85A-5448-4552-9EE6-CBF1A5AD9C40 Q36949859-0C82D274-6E2C-4A19-BF2C-D520D4A71771 Q36953090-CADDA400-1D50-4126-850D-D3E91CA93A26 Q37070476-62E4848D-0570-4E15-B0B3-B227A676BDDC Q37164563-F9F3DC65-DFF4-4310-9A7A-987D5988A6FF Q37409373-7086F808-A195-4257-8D70-1CE642E220B5 Q38156720-859B4805-10E6-4832-A100-72783FD6C03C Q38166961-D629866B-15E7-40DF-BCFD-3DEB8BECC59F Q38169085-CFB4ED0F-9069-4F2E-8AB9-513434008F95 Q38351240-4BE56E5B-A124-40A2-9BF1-ED0290038027 Q38819790-FAEF79A8-A47B-4CA5-97A2-7F416A625EF3 Q38841102-299DE685-20C0-4F83-8358-28F8B9572C9A Q38850586-DB2C8346-17D6-4A77-AE24-3B6EFFFF64F7

P2860

The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

http://www.wikidata.org/entity/Q36015358

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

The "specific" P-glycoprotein ...... sistance protein (BCRP/ABCG2).

@ast

The "specific" P-glycoprotein ...... sistance protein (BCRP/ABCG2).

@en

type

label

The "specific" P-glycoprotein ...... sistance protein (BCRP/ABCG2).

@ast

The "specific" P-glycoprotein ...... sistance protein (BCRP/ABCG2).

@en

prefLabel

The "specific" P-glycoprotein ...... sistance protein (BCRP/ABCG2).

@ast

The "specific" P-glycoprotein ...... sistance protein (BCRP/ABCG2).

@en

P1433

Q36015358-683D2E61-3C3E-495A-97E8-92E8B8AB87F7

P1476

Q36015358-EC28F29F-A535-4AD1-880F-D8D14C4D7D3E

P2093

Q36015358-3D631DCD-4FC4-4048-A013-2EBF060078BB

Q36015358-70DBB169-00E8-4FB4-9A35-5A0688D1FD4E

Q36015358-75643B23-9308-4AF0-B8C0-7A6BB1D39A8F

Q36015358-8625AE30-09D1-4711-A141-0002A5F43F6B

Q36015358-8BA44E44-28F4-4C04-A3D8-D5E303DBC174

Q36015358-9933E59C-FD2F-419C-8D15-E79D1719064F

Q36015358-B825A9B8-4133-43F7-BAB3-A26C4FAF959F

Q36015358-ECCF6797-3D32-496C-B77A-427D79CDFF5F

P2860

Q36015358-0D729A13-6A60-4ED1-836C-DBD294943405

Q36015358-0FA6766E-777E-42A8-BB25-08615EA834BB

Q36015358-12E246F0-2F0A-4BEE-9028-DCC373362805

Q36015358-1F33B357-5569-47ED-878F-1E11CBD1C011

Q36015358-2D82625E-644F-4559-BCA7-01C0D2F5FD6B

Q36015358-2E0C9D68-8A04-4B29-9200-F94CB7524638

Q36015358-2EA3021C-E2C8-498F-AEB5-F47A335262CA

Q36015358-2EDBA6A8-978B-4FB8-AF38-488D9376F201

Q36015358-3913A06B-9CD0-49FE-8924-AA5EB20B709C

Q36015358-3D35B135-B817-4FB6-A1B7-ED16211E26A0

P304

Q36015358-CEE8787D-18C4-4C84-9EA6-94F864B4C461

P31

Q36015358-F5946413-F87B-4A7C-9342-5E709E9910A3

P356

Q36015358-796D68BA-B6B2-4634-A67E-533730778EBB

P433

Q36015358-84D653F7-98C4-4F25-A12D-D28AAC5637C7

P478

Q36015358-B018F473-DCD6-45CA-9E5E-E5BD0102D248

P50

Q36015358-C0555722-A5A3-413F-BBC6-362BD4F16E27

P577

Q36015358-BF639F62-EFB2-4DF5-9E86-B79AA9C0BDFB

P5875

Q36015358-E2A4BC6C-A0D7-4977-9697-89564D10E21A

P698

Q36015358-53E66E94-52FF-4CFA-B6A0-2DD58BAAEE55

P932

Q36015358-B19CAD9F-26CB-418A-954D-B79B205ACC89

P356

P1433

ACS Chemical Neuroscience

P1476

The "specific" P-glycoprotein ...... sistance protein (BCRP/ABCG2).

@en

P2093

Matthew D Hall

http://www.w3.org/2001/XMLSchema#string

Michael M Gottesman

http://www.w3.org/2001/XMLSchema#string

Pavitra Kannan

http://www.w3.org/2001/XMLSchema#string

Robert B Innis

http://www.w3.org/2001/XMLSchema#string

Sanjay Telu

http://www.w3.org/2001/XMLSchema#string

Suneet Shukla

http://www.w3.org/2001/XMLSchema#string

Suresh V Ambudkar

http://www.w3.org/2001/XMLSchema#string

Victor W Pike

http://www.w3.org/2001/XMLSchema#string

P2860

Multidrug resistance in cancer: role of ATP-dependent transporters

A dual-fluorescence high-throughput cell line system for probing multidrug resistance.

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.

N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier

Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Drug resistance in brain diseases and the role of drug efflux transporters.

Commentary. Lysosomotropic agents.

Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.

P304

82-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/CN100078A

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Christer Halldin

P577

2010-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229017681

http://www.w3.org/2001/XMLSchema#string

P698

22778859

http://www.w3.org/2001/XMLSchema#string

P932

3369725

http://www.w3.org/2001/XMLSchema#string